LifeClean International (LCLEAN) Q4 2024 earnings summary

Executive summary

• Net sales for Q4 2024 were 10,434 TSEK, down from 14,405 TSEK in Q4 2023; full-year net sales increased to 61,152 TSEK from 52,501 TSEK year-over-year.

• Adjusted EBITDA improved to -4,628 TSEK in Q4 2024 from -6,252 TSEK in Q4 2023; full-year adjusted EBITDA was -25,552 TSEK versus -16,787 TSEK.

• Operating loss (EBIT) for Q4 2024 was -12,155 TSEK, an improvement from -13,382 TSEK in Q4 2023; full-year EBIT was -50,186 TSEK compared to -41,344 TSEK.

• Cost reductions and organizational restructuring contributed to improved quarterly results; full effect expected in Q1 2025.

• No dividend proposed for 2024.

Financial highlights

• Q4 cash flow from operations was -8,359 TSEK, nearly flat year-over-year; full-year cash flow from operations was -40,826 TSEK, down from -35,457 TSEK.

• Year-end cash position was 10,569 TSEK, up from 8,287 TSEK; available funds including unused credit were 13,706 TSEK.

• Full-year investments totaled 1,850 TSEK, mainly in patents and permits.

• Three directed share issues during the year raised 47,895 TSEK after costs.

Outlook and guidance

• Management expects cost reductions to reach full effect in Q1 2025.

• Strong growth opportunities anticipated in PFAS decontamination and healthcare segments.

• High commercial activity and increased direct customer interest, especially in PFAS-related services.

• Board intends to propose a rights issue of approximately 60 MSEK to strengthen liquidity and support growth.